Drug intelligence / Profile preview

Unicenta

Development stage: Phase 3
Lead developer: Unimedco
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

Unicenta is an investigational pharmaceutical drug developed by Unimed Pharmaceuticals. It is an injectable placental extract being studied for the treatment of menopausal syndrome. Clinical trials have shown it to be non-inferior to Melsmon, another placental extract, in improving menopausal symptoms as measured by the Kupperman index. Its therapeutic effects are believed to stem from its rich composition of biological components, including vitamins, minerals, proteins, peptides, cytokines, and hormones.

Beyond the preview

Go deeper on Unicenta.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Unicenta.

Explore the full profile